Whether compounded or brand-name, tirzepatide (GLP-1 + GIP) consistently produces greater weight loss than semaglutide alone, but it comes at a higher monthly price point throughout all providers compared
Confusing mg with insulin units could cause dangerous dosing errors
For heart failure or chronic kidney disease, the American Diabetes Association generally recommends SGLT2 inhibitors as first-line agents, with GLP-1 receptor agonists considered for their benefits on atherosclerotic cardiovascular disease, glycemic control, and weight management, or when SGLT2 inhibitors are not appropriate
The early data from obesity trials shows favorable trends in cardiovascular risk factors, but definitive outcome data remains forthcoming
Bone Miner
Weeks 9 through 12: 8mg weekly This is a significant jump, doubling the dose again from 4mg to 8mg